Inivata to Present at AACR Annual Meeting 2017

2017, News

Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, today announces the presentation of new data at the AACR Annual Meeting 2017 in Washington, USA.

The data, entitled “Comparison of enhanced Tagged-Amplicon Sequencing and digital PCR for circulating tumor DNA analysis in advanced breast cancer”, will be presented on Monday 3 April from 1:00pm – 5:00pm at the Convention Center. The poster will present the results of a new study showing ctDNA analysis using Inivata’s InVisionTM platform and Digital PCR (dPCR) have very a high concordance in mutation detection in patients with advanced breast cancer.

Clive Morris, Chief Medical Officer of Inivata, said:

“These results add to our growing body of evidence for the clinical utility of our InVisionTM platform across a number of cancer types. While we have recently announced the results of a first study of the use of a ctDNA liquid biopsy in guiding treatment decisions and delivering better patient outcomes in lung cancer patients, here we explore the utility of ctDNA in breast cancer. These data demonstrate that while our InVision platform has strong concordance with dPCR in breast cancer patients, it also yields more clinically useful biomarker information through a broad panel approach over individual mutational analysis.”


About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high caliber publications. Its lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to Follow us on Twitter @Inivata.



Media Contacts

Consilium Strategic Communications
Chris Gardner/Angela Gray/Sarah Wilson (UK)
Catherine London (US) +44 (0)20 3709 5700

Karen Chandler-Smith +44 (0)7900 430235


Our Technology

Our Solutions

Latest News